How healthy is your value analysis process? A strong program for evaluating products and new technology is essential to the cost-effective management of resources. Characteristics of a good value analysis program are offered by Barbara Strain, MA, past president of the Association of Healthcare Value Analysis Professionals. She is director of supply chain analytics for the University of Virginia (UVA) Health System in Charlottesville.
She stresses that a value analysis team isn’t just the name of a committee but a strategic, goal-oriented process. At UVA, value analysis has saved over $25 million over its 4-year history.
Strain outlined both high-level characteristics and specific elements of a successful program.
“Anyone can apply these principles, no matter how small or large your organization,” she says.
These are traits of a strong value analysis program at the organizational level.
Value analysis is a strategic objective of the organization.
It isn’t left solely to the chair of the value analysis team, who may be a middle manager.
“You can get low-hanging fruit with that approach,” Strain says. But a more robust process requires a strategic focus.
The program has specific goals. For example, at the beginning of the fiscal year, leaders set goals for the value analysis program that are achievable and monitored throughout the year.
The program is inclusive and organizationwide rather than isolated in specific departments, such as surgery, nursing, or radiology. It is a multidisciplinary effort involving the administration, physicians, clinicians, and other staff.
Everyone in the organization knows how to enter the process and use the steps required for a product to be considered for purchase. Easy-to-use guidelines and forms are available on the organization’s intranet.
“If you want people to participate, it has to be easy,” Strain says.
The value analysis process becomes embedded in the organization’s culture within the first 18 months. It becomes the way of doing business.
Value analysis is team centric. Whether the organization has a single value analysis team or ten, there is a structure so participants feel they all have a stake in the process and are pulling together.
Patients are at the center of value analysis, and the program is focused on clinical and quality outcomes. Savings follow from that. “It becomes an efficient and economical way to do business,” Strain says.
Specific elements of an effective value analysis process include:
Executive leaders are out front, saying, “This is how we are going to operate, and everyone needs to participate. We feel this is in our patients’ and institution’s best interest.”
Support is provided whenever there is pushback or the process is questioned.
A steering committee of stakeholders, such as the COO, chief of supply chain, and physicians, makes sure goals are set and monitors progress toward the goals.
There are guidelines for the team structure and how teams conduct business, including leadership, membership, and ground rules for evaluating products.
Specific value analysis teams are often designated for areas with the largest supply spend, such as the OR, cardiology, and radiology. These efforts are coordinated so products to be used by multiple units are evaluated jointly by relevant service lines. An example is a device that is inserted in the OR but that must be dressed, removed, or calibrated on the nursing unit.
A well-supported in-service program goes arm in arm with new product introduction so all clinicians learn how to use products correctly.
Physicians are involved with value analysis, with specific roles determined by each organization’s culture.
“This is where your executive leadership comes in, to help appoint and nurture surgeons to be on board with the entire program,” Strain says.
At UVA, an academic medical center, the surgical services administration, supply chain, and executive leadership have strong relationships with the chairs of the surgical departments, who in turn communicate with their faculty.
Tools are available to assist value analysis teams in their work. There is adequate support for research and data analysis.
Examples are analytics for prioritizing projects, negotiating contracts, determining potential savings, forecasting reimbursement, benchmarking, and monitoring the utilization and effectiveness of products.
A standardized process guides the analysis of a product’s potential impact and savings. Examples of considerations are:
• patient safety
• impact on clinical processes
• ease of use
• ease of conversion
• logistics of product deployment.
The analysis includes more than direct costs. Perhaps a product would lead to a change in the clinical process that would cost more money. Conversely, a product might cost more than the current product but enable you to eliminate other products or make your processes more efficient.
Guidelines are spelled out for product trials. The process is closely monitored, and results are documented. These are some UVA’s guidelines:
• Before committing to a full-fledged trial, the team may conduct a limited value analysis review to get a preliminary sense of the product’s potential clinical and financial impact.
• A trial is conducted for a specific number of cases or a specific time frame. The terms of the trial are documented contractually with the company, even if just in a purchase order.
• Clinicians’ feedback is gathered using a structured, paper-based feedback tool, and results are documented. That way, no one can say later, “I never agreed with that.”
Says Strain, “We get good participation in trials in the OR, and often have feedback from 100 to 200 individuals on an evaluation.”
Product decisions follow a structured process.
“You need to decide early in the process how decisions will be made,” says Strain. “That helps to take out the emotion or favoritism and makes it a level playing field.”
UVA uses a tool that assigns points in categories including:
• Clinical outcomes: Published evidence and impact on the clinical process
• Patient safety: Will the product affect length of stay or improve patient outcomes?
• Staff safety: Will the product decrease exposures to workplace hazards or improve clinical practice?
• Supply chain goals and strategic plan: Will the product further goals such as product standardization or replacement?
Depending on the score, the team may determine that the product doesn’t reach the threshold indicating it would add value, more information is needed before a decision can be reached, or the product is valuable and will be added to the formulary.
The score is recorded to provide documentation of the decision.
An active contracting function is available to obtain the right pricing once a product has been approved by value analysis.
The process for bringing in new products is tight to ensure that projected savings from products approved through value analysis are not diluted by other products that make their way into the system without the proper review.
Once a product is introduced, there are metrics for monitoring whether the project is contributing to the projected outcomes and savings. Did the product do what the company said it would do? Has the organization saved money, achieved the indicated patient outcome, or gained the revenue the value analysis team said it would? ❖
Resources and tools on value analysis are available to members of the Association of Healthcare Value Analysis Professionals at www.ahvap.org